ICER
-
340B, Biosimilars, Copay Accumulators, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit ManagersNot on my 2023 Bingo Card
Read more: Not on my 2023 Bingo CardWe’re in that last work week before everyone dashes off. My own clients have headed for the hills (Short Hills?) and I’ve been baking and wrapping this week. It makes me appreciate the usual day to day of policy and reimbursement more than I would have thought. Next week I’ll pull out the vision boards…
-
Caught my eye — 9/29/23
Read more: Caught my eye — 9/29/23It’s not a vacation. Let’s start with federal employees; you deserve better. You often could get paid more elsewhere but you want to serve. And instead of saying thank you, Congress asks you to take a seat on the bench and (hopefully) get backpay. It feels awful and I am so sorry you have to…
Latest news
- AMP is WAC — 03/13/26
- AMP is WAC — 3/6/26
- AMP is WAC — 02/27/26
- AMP is WAC — 2/20/26
- AMP is WAC — 2/13/26
Categories
- 340B (63)
- Affordable Care Act (22)
- Alzheimer's (11)
- Biosimilars (32)
- Caught my eye (101)
- Cell and Gene (6)
- Chevron Deference (2)
- CMMI (27)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (55)
- Drug shortages (14)
- DTC (6)
- Employers (20)
- FDA (7)
- Generics (12)
- Health Equity (4)
- Healthcare Costs (39)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (68)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (22)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (77)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (27)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (48)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (30)
- Supply Chain (7)
- Tariffs (1)
- Uncategorized (8)
- Utilization Management (11)
- Vaccines (9)
- Value (18)